Vanguard Group Inc. Has $48.64 Million Position in MiMedx Group, Inc $MDXG

Vanguard Group Inc. lifted its position in shares of MiMedx Group, Inc (NASDAQ:MDXG) by 5.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,184,262 shares of the company’s stock after buying an additional 382,623 shares during the period. Vanguard Group Inc. owned about 4.85% of MiMedx Group worth $48,637,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Phocas Financial Corp. boosted its position in shares of MiMedx Group by 17.1% during the fourth quarter. Phocas Financial Corp. now owns 492,991 shares of the company’s stock worth $3,338,000 after buying an additional 72,037 shares during the period. Allspring Global Investments Holdings LLC boosted its position in shares of MiMedx Group by 433.2% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 289,199 shares of the company’s stock worth $1,958,000 after buying an additional 234,958 shares during the period. SG Americas Securities LLC boosted its position in shares of MiMedx Group by 16.1% during the fourth quarter. SG Americas Securities LLC now owns 188,045 shares of the company’s stock worth $1,273,000 after buying an additional 26,085 shares during the period. Tudor Investment Corp ET AL acquired a new position in shares of MiMedx Group during the third quarter worth about $487,000. Finally, CIBC Bancorp USA Inc. acquired a new position in shares of MiMedx Group during the third quarter worth about $88,000. 79.15% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have recently weighed in on MDXG shares. Weiss Ratings cut MiMedx Group from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, May 4th. Cantor Fitzgerald reduced their price objective on MiMedx Group from $12.00 to $8.00 and set an “overweight” rating for the company in a research report on Tuesday, February 17th. Wall Street Zen cut MiMedx Group from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Citigroup assumed coverage on MiMedx Group in a research report on Monday, February 23rd. They set a “market outperform” rating for the company. Finally, Craig Hallum reduced their price target on MiMedx Group from $10.00 to $7.00 and set a “buy” rating for the company in a research report on Friday, April 17th. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, MiMedx Group has a consensus rating of “Moderate Buy” and a consensus target price of $8.50.

MiMedx Group Stock Performance

Shares of NASDAQ MDXG opened at $3.56 on Friday. The stock has a 50 day moving average price of $3.86 and a 200 day moving average price of $5.43. MiMedx Group, Inc has a 52 week low of $3.03 and a 52 week high of $7.99. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.81 and a current ratio of 5.39. The stock has a market capitalization of $530.26 million, a PE ratio of 17.80 and a beta of 1.46.

MiMedx Group (NASDAQ:MDXG) last issued its quarterly earnings results on Wednesday, April 29th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.02. MiMedx Group had a return on equity of 21.03% and a net margin of 7.88%.The firm had revenue of $58.99 million during the quarter, compared to analysts’ expectations of $65.80 million. Analysts predict that MiMedx Group, Inc will post -0.01 earnings per share for the current fiscal year.

MiMedx Group Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.